This year's overview of cardiac transplantation ranges from determining what impact transplant surgery has on patients' quality of life to the vexing problem of pulmonary hypertension in patients being considered for heart transplantation to mechanical circulatory assist devices important for bridging patients to cardiac transplantation. Dr. Grady notes that relatively few studies of quality of life in heart transplant recipients have been published during the last 2 decades, with most focusing on shortterm outcomes. Studies have, however, demonstrated relationships between posttransplant complications and quality of life in addition to the impact of having a ventricular assist device in place. Although the current literature suggests that quality of life globally is better after heart transplantation, both positive and negative changes have been observed. Whether quality of life improves is related to the patient's demographic characteristics, overall clinical challenges remaining after transplantation, and other major life events. Most patients report improvement in global health status and the ability to perform domestic and leisure activities. When significant detriment in quality of life is reported, challenges seem most related to the ability to work in the patient's premorbid vocational environment, and discontentment with sexual functioning and financial status. Much more work can be done in this arena, as Dr. Grady points out, with intervention studies focused on assisting patients to attain better quality of life after heart transplantation. Nonetheless, it is gratifying to see that, for the most part, quality of life is substantially improved after this operation.
Pulmonary hypertension can create substantial morbidity after heart transplant. Drs. Natale and Piña address the controversial subject of evaluation of pulmonary hypertension in patients being considered for heart transplant surgery. Indeed, they argue convincingly that assessment of the dynamics of pulmonary circulation and right ventricular function is critical. Because the degree of pulmonary hypertension and its likelihood of being reversible are linked to adverse outcome postoperatively, determination of preoperative pulmonary vascular resistance is extraordinarily important. If pulmonary vascular resistance is abnormal, reversible or irreversible classifications become important. Generally, reversible pulmonary hypertension is that noted to be responsive to a variety of pharmacologic maneuvers. This overview focuses on how pulmonary hypertension may be treated and evaluated in heart transplant candidates. Unfortunately, to date, there is no reliable hemodynamic threshold beyond which right ventricular failure is certain to occur and transplantation cannot be accomplished. Further exploration of this important and timely topic will give greater insight into the thorny dilemma of heart transplant candidate selection.
Drs. Loebe, Koerner, Lafuente, and Noon have tremendous experience with use of a variety of left ventricular assist devices, most recently the continuous flow impeller-driven Micromed ventricular assist pump (Micromed Technologies, Houston, TX). Selection of patients for device implantation as a bridge to transplant can be a challenging dilemma. Perhaps the availability of a broader spectrum of devices will allow better tailoring of a given device to different clinical situations. For example, large patients with complete failure of the heart may be better served with an intracorporeal pulsatile device, whereas patients needing ventricular assistance as opposed to ventricular replacement may do well with a continuous flow device, which is generally smaller, easier to insert, and less mechanically complicated. As these authors point out, the best candidate for mechanical support is a patient who is stable but requiring chronic intravenous medical support therapeutics. A wearable left ventricular assist device is, perhaps, the treatment of choice in this patient. On the other end of the spectrum are patients with cardiogenic shock and both right and left ventricular failure. Biventricular support likely is the best tack to sail with these patients. Outcomes after ventricular assist device insertion are, to a large degree, determined by the amount of irreversible damage that occurs during cardiac failure. Unfortunately, device-related events such as infection, emboli, and device failure can contribute to long-term problems during the bridge to transplant period.
As an appropriate addition to this consideration of devices for bridge to transplant, Dr. Deng overviews plans by the International Society for Heart and Lung Transplantation to create a mechanical circulatory support device database. Fair and appropriate outcomes information is critical to objective assessment of this technology. The efforts by Dr. Deng and his colleagues at the International Society for Heart and Lung Transplantation should be applauded, encouraged, and supported because of the valuable data that will emerge from this registry. Dr. Deng eloquently overviews the nuances of this database.
Finally, Dr. Mehra and his colleagues at the Oschner Clinic in New Orleans, LA tackle the vexing dilemma of allosensitization in patients waiting for heart transplantation. This timely review gives suggestions regarding administration of intravenous immunoglobulin, apheresis, and combination therapies using potent immunosuppression (cyclophosphamide in particular). Perhaps most important is the plea made for better and more organized study of this challenge.
